StockVS

EDAP TMS S.A. (EDAP) Stock Analysis

Healthcare

EDAP TMS S.A.

$4.31

+$0.01 (+0.23%)

Last Updated: May 26, 2026

Price History

Analysis

Company Overview

EDAP TMS S.A. operates as a developer, manufacturer, promoter, and distributor of minimally-invasive medical devices designed specifically for urology applications. The company leverages proprietary ultrasound technology to create products that are marketed and distributed across key regions including Asia, France, the United States, and various international markets. This entity functions within the broader Healthcare sector, specifically specializing in the Medical Distribution industry, which implies a focus on the supply chain and commercialization of essential medical equipment rather than direct patient care services. With a market capitalization of $138.72M and annual revenue of $62.42M, the company represents a mid-sized entity within its niche. These valuation and revenue figures indicate that EDAP TMS S.A. has established a significant commercial footprint for specialized urological devices, yet the scale suggests it operates with a capitalization typical of companies still navigating the complexities of high-margin technology deployment and distribution expansion.

Financial Health

The company reported revenue of $62.42M for the trailing twelve months, yet this top-line figure masks a net income of $-25,883,000 and an EBITDA of $-19,290,000. The substantial gap between the $62.42M revenue and the negative net income reveals a cost structure where operating expenses and other deductions are significantly exceeding gross profits, resulting in a loss that is nearly 41% of total sales. This divergence between revenue generation and profitability indicates that the company is currently investing heavily in operations or facing elevated cost pressures that have not yet been offset by efficient scaling. Regarding cash generation, the free cash flow stands at $-13,066,000, which indicates that the company is consuming cash reserves to fund its operations and strategic initiatives rather than generating surplus liquidity for debt repayment or shareholder returns. The balance sheet reflects a leveraged position with total debt of $20.70M against cash holdings of $17.41M, resulting in a debt-to-equity ratio of 125.26. This high leverage ratio suggests that the company relies heavily on financial obligations relative to its equity base, which limits financial flexibility and increases sensitivity to interest rate fluctuations or revenue shortfalls. Liquidity management is supported by a current ratio of 1.54, indicating that the company possesses sufficient current assets to cover its short-term liabilities, though the margin is not excessively wide. Furthermore, the return on equity is -90.2% and the return on assets is -17.8%, metrics that reveal management has not yet achieved profitability per unit of capital employed or asset base. These negative return figures underscore the challenges in converting operational activities into value for shareholders at this specific point in the company's lifecycle.

Valuation Assessment

Valuation multiples for EDAP TMS S.A. present a complex picture due to the company's unprofitable status, with a trailing P/E ratio listed as N/A and a forward P/E of -6.61. The negative forward P/E implies that the market is pricing in expectations of future earnings recovery, as the current trajectory does not support a traditional earnings-based valuation multiple. Asset valuation is highlighted by a price-to-book ratio of 7.24, which indicates that the market values the company at more than seven times its net asset value, suggesting a significant premium attributed to its intangible assets, technology, or growth potential despite current losses. Alternative valuation metrics further illustrate this disparity, with a price-to-sales ratio of 2.22 and an EV/EBITDA of -7.37, suggesting that investors are focusing on revenue quality and market share rather than current earnings power. The stock price has exhibited high volatility, trading between a 52-week high of $5.05 and a 52-week low of $1.21. Based on the provided range, the current trading price sits at a level that reflects significant downside from the recent peak, though the specific percentage below the high requires the current price which is not explicitly defined in the source text, so the absolute range defines the volatility envelope. The beta is listed as N/A, meaning that volatility relative to the broader market cannot be quantified using the standard beta metric from the available data.

Growth & Income

Growth metrics show a revenue growth rate of -6.8% year-over-year, while earnings growth is N/A due to the negative income figures. The contraction in revenue combined with the absence of positive earnings growth implies that the company is currently facing headwinds in its core distribution business that are preventing both top-line expansion and profitability improvement. Regarding income distribution, the company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%. Consequently, the company reinvests all available earnings or capital into growth initiatives rather than distributing cash to shareholders, which is a common strategy for unprofitable firms attempting to build market presence. The overall growth and income profile for EDAP TMS S.A. is characterized by negative revenue momentum and a complete reliance on capital markets or internal cash reserves to fund operations without shareholder distributions.

Peer Comparison

EDAP TMS S.A. (EDAP) operates in the Medical Distribution industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
EDAP TMS S.A. EDAP $161.55M N/A
McKesson Corporation MCK $90.68B 19.6
Cencora, Inc. COR $52.68B 20.8
Cardinal Health, Inc. CAH $46.93B 30.6

The Medical Distribution industry average P/E ratio is 23.3x. EDAP TMS S.A. trades at a P/E of N/A.

This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.

About EDAP TMS S.A.

EDAP TMS S.A., a medical technology company, engages in the development, manufacturing, marketing, and sale of non-invasive therapeutic ultrasound and energy-based medical devices in Asia, France, the United States, and internationally. The company operates through High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution segments. The HIFU segment develops, manufactures, markets, and distributes non-invasive robotic HIFU systems for urology-related and other indications. This segment also offers Focal One, a HIFU robotic system to treat patients diagnosed with prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL segment manufactures and markets lithotripter for the treatment of urinary tract stones; and provides disposables, replacement parts, and services for lithotripters. This segment also sells spare parts and disposables, such as electrodes. The Distribution segment markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. It markets and sells its products through its direct marketing, sales channels, and third-party distributors and agents. The company serves academic, public, and private hospitals, as well as clinics. The company has a strategic collaboration with Telix Pharmaceuticals Limited to develop clinical workflows combining PSMA PET imaging and Focal One Robotic HIFU for prostate cancer. EDAP TMS S.A. was incorporated in 1979 and is headquartered in Vaulx-en-Velin, France.

Visit website →

Key Statistics

Market Cap
$161.55M
P/E Ratio
N/A
52-Week High
$5.05
52-Week Low
$1.21
Avg Volume
36.42K
Beta
-0.10

Data provided by Yahoo Finance via yfinance. Updated daily.

Company Info

Exchange
NASDAQ
Country
France
Employees
289